BioSpace News Archive

ADVANZ PHARMA Corp. Limited (“ADVANZ PHARMA” or “the Company”), a global pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with enhanced access to high quality, niche-established medicines, today announced that it closed its previously announced acquisition of specialty pharmaceutical company Correvio Pharma Corp. (“Correvio”) (NASDAQ: CORV) (TSX: CORV).

Tampa General Hospital’s top infection prevention experts are consulting with leading organizations in Tampa Bay and beyond to help them keep employees, customers and visitors safer from COVID-19 and other infectious diseases

Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Jefferies 2020 Virtual Healthcare Conference on Thursday, June 4, 2020, at approximately 9:00 a.m. (ET).

Trinity Life Sciences, a leader in global life sciences solutions, found that the majority of in-depth discussions at last week’s virtual TGaS Spring Summit focused on how pharmaceutical companies’ commercial operations need to adjust in response to the current pandemic.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), today announced the closing of its initial public offering of 9,432,949 shares of its common stock, including the exercise in full of the underwriters’ option to purchase 1,230,384 additional shares of common stock, at the initial public offering price of $19.00 per share

MedMira Inc. (MedMira) (TSXV: MIR) announces that company has entered into an Exclusive Distribution Agreement with Webb Diagnostic Technologies, Inc., (WebbDX) for the distribution of MedMira’s REVEALCOVID-19™ Total Antibody Test.

Loan taken out with Banque Populaire du Sud and BNP Paribas in the form of PGE

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the completion of its End-of-Pha

Acquist Therapeutics, Inc ., a biopharmaceutical company committed to new treatment for patients with inflammatory diseases, announced the appointment of two new members to its Board of Directors – Thomas P. Haverty , MD, and John R. Redman , MD. “We are honored that these experienced executives are joining our Board of Directors,

Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present a corporate overview for 2020 at BIO Digital from June 8-12. For 2020, the BIO International Convention has transitioned to a new, virtual event format. The Company will present its corporate overview for 2020 with a special focus on multiple growth opportunitie